|[July 02, 2014]
AIMM Therapeutics' Partner MedImmune Starts Clinical Studies with RSV Antibody
AMSTERDAM --(Business Wire)--
AIMM Therapeutics, a leading human therapeutic antibody company, today
announced that its partner MedImmune, LLC, the global biologics unit of
AstraZeneca, has initiated phase I clinical studies with MEDI8897, a
best-in-class antibody for the treatment of respiratory syncytial virus
(RSV) infections in young, at risk children. MEDI8897 originated from
AIMM's D25 antibody. Under the terms of their partnering agreement, AIMM
will receive a non-disclosed milestone payment from MedImmune.
D25 was developed from immortalized B cells of an individual exposed to
RSV utilizing AIMM's proprietary antibody technology platform.
Preclinical studies have shown that D25 neutralizes RSV with high
efficiency by recognizing a unique epitope on the prefusion structure of
the F protein expressed on the virus coat.
"MedImmune is the world leader in RSV infection drug development so the
valdation associated with the initiation of clinical studies with
MEDI8897 is very pleasing to see. This milestone is further confirmation
of AIMM's unique capabilities to discover exceptional human antibodies,
with high therapeutic potency, against biological targets that normally
are difficult to address," said Dr. Jan de Vries, AIMM's CEO.
MedImmune's Head of Research Dr. Yong-Jun Liu added: "We are excited
that our partnership with AIMM Therapeutics resulted in the development
of a powerful RSV antibody aimed at preventing the high morbidity and
mortality of RSV infections in young children at risk."
About AIMM Therapeutics
AIMM Therapeutics (AIMM) is a leading antibody company that based on its
synergistic, state-of-the-art antibody technology platform develops high
affinity human monoclonal antibodies directly from immortalized and
selected B cells of individuals who produce antibodies with high
therapeutic value and of a variety of non-human species, including
rabbits. AIMM antibodies can be further affinity matured in a
proprietary process that does not require molecular engineering. AIMM
has a broad product pipeline targeted at various cancers and chronic
infections. AIMM has two antibodies in clinical trials and has partnered
with companies such as MedImmune/ AstraZeneca, Genentech/Roche, Johnson
& Johnson and Cosmo Pharmaceuticals. For more information: www.aimmtherapeutics.com.
[ Back To TMCnet.com's Homepage ]